Homozygous Variant of Antithrombin III : AT III Fontainebleau

Summary

A qualitative defect of antithrombin III (AT III) was demonstrated in four members of a large Tunisian family by the discrepancy between a normal amount of antigen and decreased or absent heparin cofactor activity. The propositus, a 3-year-old girl, died from massive intracardiac thrombosis despite oral anticoagulant therapy. Heparin cofactor activity measured in the presence of thrombin or F. Xa was undetectable in her plasma. Anti-F. Xa activity was also absent when using low molecular weight heparin or a synthetic pentasaccharide, representing the binding site to AT III. The lack of affinity of the propositus AT III for heparin was demonstrated by two-dimensional immunoelectrophoresis and chromatography on heparin-Sepha-rose. The parents, first cousins, and the sister of the propositus also demonstrated a qualitative abnormality of AT III, with levels of heparin cofactor activity close to 50% of the normal range. Our data support the view that the abnormal protein was present at the heterozygous state in the parents and sister and at the homozygous state in the propositus. None of the affected family members had thrombotic episodes, except for the propositus. The name of AT III Fontainebleau is proposed for this variant.

Keywords

Antithrombin III - Variant - Heparin - Homozygous - Thrombosis

• References

• 1 Sas G, Blasko G, Banhegyi D, Jako J, Palos LA. Abnormal antithrombin III (antithrombin III “Budapest”) as a cause of a familial thrombophilia. Thromb Diath Haemorrh 1974; 32: 105-115
• 2 Sas G. Hereditary antithrombin III deficiency: biochemical aspects. Haematologia (Budap.) 1984; 17: 81-86
• 3 Tran TH, Bounameaux H, Bondeli C, Honkanen H, Marbet GA, Duckert F. Purification and partial characterization of a hereditary abnormal antithrombin III fraction of a patient with recurrent thrombophlebitis. Thromb Haemostas 1980; 44: 87-91
• 4 Wolf M, Boyer C, Lavergne JM, Larrieu MJ. A new familial variant of antithrombin III: “Antithrombin III Paris”. Br J Haematol 1982; 51: 285-295
• 5 Sorensen PJ, Sas G, Peto I, Blasko Gy, Kremmer T, Samu A. Distinction of two pathologic antithrombin III molecules: antithrombin III “Aalborg” and antithrombin III “Budapest”. Thromb Res 1982; 26: 211-219
• 6 Sakuragawa N, Takahashi K, Kondo SI, Koide T. Antithrombin III Toyama: A hereditary abnormal antithrombin III of a patient with recurrent thrombophlebitis. Thromb Res 1983; 31: 305-317
• 7 Koide T, Takahashi K, Odani S, Ono T, Sakuragawa N. Isolation and characterization of a hereditary abnormal antithrombin III “Antithrombin III Toyama”. Thromb Res 1983; 31: 319-328
• 8 Bauer KA, Ashenhurst JB, Chediak J, Rosenberg RD. Antithrombin “Chicago”. A functionally abnormal molecule with increased heparin affinity causing familial thrombophilia. Blood 1983; 62: 1242-1250
• 9 Barbui T, Finazzi G, Rodeghiero F, Dini E. Immunoelectrophoresis evidence of a thrombin-induced abnormality in a new variant of hereditary dysfunctional antithrombin III (AT III “Vicenza”). Br J Haematol 1983; 54: 561-565
• 10 Girolami A, Fabrios F, Cappellato G, Sainati L, Boeri G. Antithrombin III (AT III) Padua 2: A new congenital abnormality with defective heparin cofactor activities but no thrombotic disease. Blut 1983; 47: 093-103
• 11 Chasse JF, Esnard F, Guitton JD, Mouray H, Perigois F, Fauconneau G, Gauthier F. An abnormal plasma antithrombin with no apparent affinity for heparin. Thromb Res 1984; 34: 297-302
• 12 Jorgensen M, Petersen LC, Thorsen S. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding. J Lab Clin Med 1984; 104: 245-256
• 13 Girolami A, Rubetelli M, Marafiotti F, Zamboni A, Vicarioto MA. Crossed Immunoelectrophoresis in the study of abnormal antithrombin III: behavior of AT III Trento. Brit J Haematol 1983; 55: 559-561
• 14 Howarth DJ, Samson D, Stirling Y, Seghatchian MJ. Antithrombin III “Northwick Park”: A variant antithrombin with normal affinity for heparin but reduced heparin cofactor acitivity. Thromb Haemostas 1985; 53: 314-319
• 15 Tengborn L, Frohm B, Nilsson LE, Nilsson IM. A Swedish family with abnormal antithrombin III. Scand J Haematol 1985; 34: 412-416
• 16 Aiach M, Nora M, Fiessinger J-N, Roncato M, François D, Alhenc Gelas M. A functional abnormal antithrombin III (AT III) deficiency: AT III Charleville. Thromb Res 1985; 39: 559-570
• 17 Wolf M, Boyer C, Tripodi A, Meyer D, Larrieu MJ, Mannucci PM. Antithrombin Milano: A new variant with monomeric and dimeric inactive antithrombin III. Blood 1985; 65: 496-500
• 18 Mannucci PM, Federici AB, Sirchia G. Hemostasis testing during massive blood replacement. A study of 172 cases. Vox Sang 1982; 42: 113-123
• 19 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gels containing antibodies. Anal Biochem 1966; 15: 45-52
• 20 Abildgaard U, Larsen ML. Assay of dermatan sulfate cofactor (heparin cofactor II) activity in human plasma. Thromb Res 1984; 35: 257-266
• 21 Boyer C, Rothschild C, Wolf M, Amiral J, Meyer D, Larrieu MJ. A new method for the estimation of protein C by ELISA. Thromb Res 1984; 36: 579-589
• 22 Francis RB, Patch MJ. A functional assay for protein C in human plasma. Thromb Res 1983; 32: 605-613
• 23 Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410
• 24 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169
• 25 Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-499
• 26 Villanueva GB. Predictions of the secondary structure of antithrombin III and the location of the heparin-binding site. J Biol Chem 1984; 259: 2531-2536
• 27 Pecon JM, Blackburn MN. Pyridoxylation of essential lysines in the heparin binding site of antithrombin III. J Biol Chem 1984; 259: 935-938
• 28 Koide T, Odani S, Takahashi K, Ono T, Sakuragawa N. Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proc Natl Acad Sci USA 1984; 81: 289-293
• 29 Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparin-like molecules bound to the endothelium. J Clin Invest 1984; 74: 341-350
• 30 Stern D, Nawroth P, Marcum J, Handley D, Kisiel W, Rosenberg R, Stern K. Interaction of antithrombin III with bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity. J Clin Invest 1985; 75: 272-279